| Literature DB >> 25098365 |
Nicola Maffulli1, Umile Giuseppe Longo2, Mattia Loppini2, Alessandra Berton2, Filippo Spiezia2, Vincenzo Denaro2.
Abstract
The purpose of this systematic review was to address the treatment of rotator cuff tears by applying tissue engineering approaches to improve tendon healing, specifically platelet rich plasma (PRP) augmentation, stem cells, and scaffolds. Our systematic search was performed using the combination of the following terms: "rotator cuff", "shoulder", "PRP", "platelet rich plasma", "stemcells", "scaffold", "growth factors", and "tissue engineering". No level I or II studies were found on the use of scaffolds and stem cells for rotator cuff repair. Three studies compared rotator cuff repair with or without PRP augmentation. All authors performed arthroscopic rotator cuff repair with different techniques of suture anchor fixation and different PRP augmentation. The three studies found no difference in clinical rating scales and functional outcomes between PRP and control groups. Only one study showed clinical statistically significant difference between the two groups at the 3-month follow up. Any statistically significant difference in the rates of tendon rerupture between the control group and the PRP group was found using the magnetic resonance imaging. The current literature on tissue engineering application for rotator cuff repair is scanty. Comparative studies included in this review suggest that PRP augmented repair of a rotator cuff does not yield improved functional and clinical outcome compared with non-augmented repair at a medium and long-term followup.Entities:
Year: 2011 PMID: 25098365 PMCID: PMC3216270 DOI: 10.1155/2012/418086
Source DB: PubMed Journal: Stem Cells Int Impact factor: 5.443
Figure 1Flowchart of the search strategy and selection of articles.
Study and demographic data.
| Study | Level of evidence | Patients | Mean age | Men | Followup | Size of lesion | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Castricini et al. [ | I | Control group | 45 | 55.2 (37–69) | 23/22 | 20.2 (16–30) | 20 Small RCT | 25 Medium RCT | 0 | 0 |
| PRP group | 43 | 55.5 (41–72) | 17/26 | 18 Small RCT | 25 Medium RCT | 0 | 0 | |||
|
| ||||||||||
| Randelli et al. [ | I | Control group | 27 | 59.5 (±10.7) | 13 | 23 | 12 Minor | 7 Moderate | 4 Severe | 4 Massive |
| PRP group | 26 | 61.6 (±8.3) | 8 | 9 Minor | 7 Moderate | 3 Severe | 7 Massive | |||
|
| ||||||||||
| Jo et al. [ | II | Control group | 23 | 59.80 (±8.84) | 9 | 20.30 (±1.89) | 2 Small RCT | 15 Medium RCT | 3 Large RCT | 3 Massive RCT |
| PRP group | 19 | 61.80 (±8.86) | 6 | 18.94 (±1.63) | 1 Small RCT | 7 Medium RCT | 5 Large RCT | 6 Massive RCT | ||
RCT: rotator cuff tear.
Surgical techniques and concomitant procedures.
| Study | Surgical technique | Total | Type of anchors | Type and size of suture | Type of knots | Concomitant procedures | Complications | |
|---|---|---|---|---|---|---|---|---|
| Castricini et al. [ | Control group | Arthroscopic RC repair with double-row technique | 2 for each patients | Metal suture anchors (Fastin RC Anchor; DePuy Mitek) | No. 2 Ethibond Excel (Ethicon) | Medial sutures: nonsliding knot in a mattress configuration; lateral sutures: sliding knot | Acromionplasty 25; Tenodesis 22; Tenotomy 5 | 0 |
| PRP group | Arthroscopic RC repair with double-row technique with membrane of PRFM augmentation | 2 for 41 patients and 3 for 2 patients | Acromionplasty 12; Tenodesis 21; Tenotomy 3 | 0 | ||||
|
| ||||||||
| Randelli et al. [ | Control group | Arthroscopic RC repair with single-row technique | 1.6 ± 0.7 | Absorbable suture anchors | — | — | Acromionplasty 27; Tenodesis 1; Tenotomy 18 | 0 |
| PRP group | Arthroscopic RC repair with single-row technique and injection of PRP and autologous thrombin | 2 ± 0.9 | — | — | Acromionplasty 26; Tenodesis 4; Tenotomy 15 | 0 | ||
|
| ||||||||
| Jo et al. [ | Control group | Arthroscopic RC repair with suture bridge technique | 2 or 3 for small/medium tears; 3 to 5 for large/massive tear | Absorbable suture anchors | No. 1 Polydioxanone II suture (Ethicon) | Medial sutures: slippage proof knot; knotless suture anchor repair | Acromionplasty 4 | 0 |
| PRP group | Arthroscopic RC repair with suture bridge technique and application of PRP gel | Acromionplasty 3 | 0 | |||||
RC: rotator cuff; PRFM: platelet-rich fibrin matrix.
Clinical outcomes.
| Study | Outcome measures | Pre-op. | 3 days | 1 month | 3 months | 6 months | 12 months | 16 months | 24 months | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Constant score |
| ||||||||||
| Castricini et al., 2011 [ | Control group | 42.9 (22–55) | 88.4 (54–100) | <0.001 | |||||||
| PRP group | 42 (30–53) | 88.4 (72–99) | <0.001 | ||||||||
|
| 0.44 | ||||||||||
|
| |||||||||||
| Randelli et al., 2011 [ | Constant score | ||||||||||
| Control group | 42.2 ± 15.2 | 57.8 ± 11 | 72.3 ± 12.6 | 75.7 ± 9.5 | 78.7 ± 10 | ||||||
| PRP group | 44 ± 16.5 | 65 ± 9 | 73.1 ± 8.7 | 78.3 ± 6.4 | 82.4 ± 6.3 | ||||||
|
| 0.6 | 0.02 | 0.7 | 0.3 | 0.1 | ||||||
| UCLA | |||||||||||
| Control group | 14.5 ± 5.6 | 24.2 ± 4.9 | 29.2 ± 4.9 | 31 ± 4.1 | 31.3 ± 4.1 | ||||||
| PRP group | 15.3 ± 5.9 | 26.9 ± 3 | 30.6 ± 4.1 | 31.2 ± 5.2 | 33.3 ± 2.2 | ||||||
|
| 0.6 | 0.03 | 0.3 | 0.7 | 0.06 | ||||||
| SER (Kg) | |||||||||||
| Control group | 2.3 ± 2 | 2.1 ± 1.3 | 3.3 ± 1.3 | 3.7 ± 1.5 | 4 ± 1.9 | ||||||
| PRP group | 1.9 ± 1.7 | 3 ± 1.6 | 3.9 ± 2.1 | 4.2 ± 2.8 | 4.3 ± 2.3 | ||||||
|
| 0.4 | 0.04 | 0.2 | 0.5 | 0.5 | ||||||
| SST | |||||||||||
| Control group | 4.7 ± 2.8 | 7.1 ± 2.7 | 10.5 ± 2.3 | 10.6 ± 1.5 | 10.9 ± 1.4 | ||||||
| PRP group | 4.8 ± 3.1 | 8.9 ± 2.2 | 10.6 ± 1.4 | 11.1 ± 0.9 | 11.3 ± 0.9 | ||||||
|
| 0.9 | 0.02 | 0.9 | 0.3 | 0.3 | ||||||
| VAS | |||||||||||
| Control group | 6.4 ± 2 | 6.3 ± 2.8 | 2.4 ± 2.6 | ||||||||
| PRP group | 4.8 ± 2 | 4 ± 3.2 | 1.1 ± 2.2 | ||||||||
|
| 0.003 | 0.007 | 0.01 | ||||||||
|
| |||||||||||
| Jo et al. [ | Constant Score | ||||||||||
| Control group | 50.78 ± 16.04 | 46.10 ± 17.75 | 64.56 ± 15.98 | 81.36 ± 11.97 | 82.00 ± 13.02 | ||||||
| PRP group | 46.47 ± 16.50 | 33.47 ± 14.39 | 63.36 ± 11.73 | 77.65 ± 13.02 | 79.12 ± 13.42 | ||||||
|
| 0.397 | 0.036 | 0.910 | 0.493 | 0.476 | ||||||
| UCLA | |||||||||||
| Control group | 16.78 ± 4.73 | 22.00 ± 4.01 | 25.94 ± 4.84 | 29.77 ± 4.36 | 30.83 ± 4.96 | ||||||
| PRP group | 15.89 ± 4.98 | 18.00 ± 7.47 | 26.27 ± 4.43 | 30.12 ± 6.04 | 31.78 ± 6.15 | ||||||
|
| 0.558 | 0.061 | 0.827 | 0.708 | 0.579 | ||||||
| ASES | |||||||||||
| Control group | 49.60 ± 17.74 | 60.58 ± 16.33 | 71.75 ± 18.21 | 89.19 ± 10.73 | 89.92 ± 17.03 | ||||||
| PRP group | 43.95 ± 20.44 | 46.22 ± 20.06 | 72.63 ± 13.63 | 86.26 ± 19.95 | 87.61 ± 24.83 | ||||||
|
| 0.343 | 0.031 | 0.530 | 0.712 | 0.744 | ||||||
| DASH | |||||||||||
| Control group | 45.69 ± 25.51 | 38.83 ± 20.14 | 23.80 ± 16.74 | 9.20 ± 9.87 | 8.48 ± 14.05 | ||||||
| PRP group | 52.85 ± 25.29 | 49.61 ± 23.12 | 24.85 ± 16.52 | 12.84 ± 18.89 | 13.19 ± 25.45 | ||||||
|
| 0.369 | 0.166 | 0.703 | 0.588 | 0.473 | ||||||
| SST | |||||||||||
| Control group | 5.17 ± 2.99 | 5.40 ± 3.57 | 9.06 ± 5.45 | 10.64 ± 1.71 | 10.57 ± 1.73 | ||||||
| PRP group | 4.63 ± 3.29 | 4.40 ± 2.50 | 8.36 ± 2.25 | 9.59 ± 2.85 | 9.83 ± 3.31 | ||||||
|
| 0.579 | 0.369 | 0.982 | 0.206 | 0.355 | ||||||
| SPADI | |||||||||||
| Control group | 46.25 ± 24.05 | 39.50 ± 23.02 | 25.71 ± 15.52 | 9.83 ± 10.59 | 10.08 ± 16.32 | ||||||
| PRP group | 54.47 ± 28.72 | 56.33 ± 23.97 | 28.69 ± 14.29 | 11.72 ± 18.22 | 12.03 ± 24.96 | ||||||
|
| 0.318 | 0.045 | 0.745 | 0.869 | 0.673 | ||||||
VAS: Visual Analog Score for Pain; PRP: platelet rich plasma; SER: strength in external rotation; UCLA: University of California; SST: Simple Shoulder Test; ASES: American Shoulder and Elbow Society; DASH: Disabilities of the Arm, Shoulder and Hand; SPADI: Shoulder Pain and Disability Index.